Kathleen A Martin, PhD

Associate Professor of Medicine (Cardiology) and of Pharmacology; Associate Professor of Pharmacology

Research Interests

Cardiology; Cardiovascular Diseases; Pharmacology; Vascular Diseases; Signal Transduction

Research Organizations

Cardiovascular Medicine: Martin Lab | Yale Cardiovascular Research Center

Faculty Research

Stem Cell Center, Yale

Vascular Biology and Therapeutics Program

Office of Cooperative Research

Research Summary

Our overall goal is to understand how regulation of the muscular layer of blood vessels contributes to normal vessel function and to cardiovascular disease. Hyperproliferation or dysfunction in vascular smooth muscle cells contributes to atherosclerosis, hypertension, organ transplant failure, and failure of revascularization therapies such as balloon angioplasty or bypass surgery. By understanding the regulatory mechanisms of vascular smooth muscle, we aim to develop new therapies for treatment and prevention of cardiovascular diseases.

Specialized Terms: Vascular smooth muscle; Differentiation; Signal transduction; Transcription; Epigenetics

Extensive Research Description

Brief Research Summary

Our studies are aimed at understanding the molecular mechanisms that regulate vascular smooth muscle cell (SMC) phenotype. Mature SMC retain the ability to de-differentiate and re-enter the cell cycle. This is essential for such processes as angiogenesis, but also contributes to the pathogenesis of atherosclerosis, intimal hyperplasia, and restenosis.

Regulation of Vascular Smooth Muscle Phenotype: Rapamycin-eluting stents have revolutionized treatment of coronary artery disease, dramatically reducing restenosis. While highly efficacious in this localized drug delivery setting, systemic high dose rapamycin is not a viable strategy for other vascular diseases due to adverse effects. Our goal is to understand the molecular mechanisms by which rapamycin beneficially affects SMC phenotype, in order to develop novel therapeutics. Identifying the smooth muscle-specific targets of the mTOR pathway may generate new therapeutic strategies for treatment and prevention of atherosclerosis and intimal hyperplasia.

Epigentic regulation: We have recently discovered that the mTOR pathway promotes VSMC differentiation through regulation of the DNA modifying enzyme TET2. We have identified TET2 as a novel master epigenetic regulator of VSMC phenotype. Notably, TET2 promotes changes in chromatin that lead to expression of prodifferentiation genes including SRF and myocardin and contractile genes such as SM-MHC and SM-alpha actin, while concomitantly downregulating expression of de-differentiation-associated genes including KFL4.

Akt signaling: We have previously shown that rapamycin feedback signaling through Akt2 underlies its effects on VSMC phenotype in vitro. We are currently studying the effects of Akt isoforms in rapamycin therapeutic response in vivo and have uncovered exciting Akt isoform-specific effects that reveal opposing roles for these nhighly related kinases. We are also studying Akt-regulated transcription factors and cyto skeletal-associated proteins that contribute to VSMC phenotypic modulation.

Selected Publications

Full List of PubMed Publications

Edit this profile

Contact Info

Kathleen A Martin, PhD
Mailing Address
Section of Cardiovascular Medicine
PO Box 208017

New Haven, CT 06520-8017

The Martin Lab